BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 22981893)

  • 1. Characterization of the antibody response elicited by immunization with pneumococcal surface protein A (PspA) as recombinant protein or DNA vaccine and analysis of protection against an intranasal lethal challenge with Streptococcus pneumoniae.
    Vadesilho CF; Ferreira DM; Moreno AT; Chavez-Olortegui C; Machado de Avila RA; Oliveira ML; Ho PL; Miyaji EN
    Microb Pathog; 2012; 53(5-6):243-9. PubMed ID: 22981893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production.
    Ferreira DM; Darrieux M; Oliveira ML; Leite LC; Miyaji EN
    Clin Vaccine Immunol; 2008 Mar; 15(3):499-505. PubMed ID: 18184825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.
    Chen X; Li B; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Zhang Y; Wu Y
    Med Microbiol Immunol; 2019 Apr; 208(2):215-226. PubMed ID: 30707297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A).
    Ferreira DM; Oliveira ML; Moreno AT; Ho PL; Briles DE; Miyaji EN
    Microb Pathog; 2010 Jun; 48(6):205-13. PubMed ID: 20206678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses.
    Miyaji EN; Dias WO; Tanizaki MM; Leite LC
    FEMS Immunol Med Microbiol; 2003 Jun; 37(1):53-7. PubMed ID: 12770760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.
    Lin H; Peng Y; Lin Z; Zhang S; Guo Y
    Microb Pathog; 2015; 83-84():35-40. PubMed ID: 25959527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA vaccines expressing pneumococcal surface protein A (PspA) elicit protection levels comparable to recombinant protein.
    Ferreira DM; Miyaji EN; Oliveira MLS; Darrieux M; Arêas APM; Ho PL; Leite LCC
    J Med Microbiol; 2006 Apr; 55(Pt 4):375-378. PubMed ID: 16533983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multivalent Pneumococcal Protein Vaccines Comprising Pneumolysoid with Epitopes/Fragments of CbpA and/or PspA Elicit Strong and Broad Protection.
    Chen A; Mann B; Gao G; Heath R; King J; Maissoneuve J; Alderson M; Tate A; Hollingshead SK; Tweten RK; Briles DE; Tuomanen EI; Paton JC
    Clin Vaccine Immunol; 2015 Oct; 22(10):1079-89. PubMed ID: 26245351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant BCG expressing a PspA-PdT fusion protein protects mice against pneumococcal lethal challenge in a prime-boost strategy.
    Goulart C; Rodriguez D; Kanno AI; Lu YJ; Malley R; Leite LC
    Vaccine; 2017 Mar; 35(13):1683-1691. PubMed ID: 28242071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
    Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ
    Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced protective immunity against pneumococcal infection with PspA DNA and protein.
    Moore QC; Bosarge JR; Quin LR; McDaniel LS
    Vaccine; 2006 Jul; 24(29-30):5755-61. PubMed ID: 16759765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
    Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
    Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection.
    Hanniffy SB; Carter AT; Hitchin E; Wells JM
    J Infect Dis; 2007 Jan; 195(2):185-93. PubMed ID: 17191163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.
    Li B; Chen X; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Wu Y
    Microb Pathog; 2018 Oct; 123():115-119. PubMed ID: 29959043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades.
    Miyaji EN; Ferreira DM; Lopes AP; Brandileone MC; Dias WO; Leite LC
    Infect Immun; 2002 Sep; 70(9):5086-90. PubMed ID: 12183557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae.
    Xin W; Li Y; Mo H; Roland KL; Curtiss R
    Infect Immun; 2009 Oct; 77(10):4518-28. PubMed ID: 19687204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
    Nguyen CT; Kim SY; Kim MS; Lee SE; Rhee JH
    Vaccine; 2011 Aug; 29(34):5731-9. PubMed ID: 21696869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
    Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of antibodies and IL17-mediated immunity in protection against pneumococcal otitis media.
    Habets MN; van Selm S; van Opzeeland FJ; Simonetti E; Hermans PWM; de Jonge MI; Diavatopoulos DA
    Vaccine; 2016 Nov; 34(48):5968-5974. PubMed ID: 27771185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.
    da Silva MA; Converso TR; Gonçalves VM; Leite LCC; Tanizaki MM; Barazzone GC
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28637805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.